UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 10, 2024

SCYNEXIS, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	**001-36365**	**56-2181648**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

1 Evertrust Plaza **13th Floor** **Jersey City, New Jersey**	**07302-6548**
(Address of Principal Executive Offices)	**(Zip Code)**

Registrant's Telephone Number, Including Area Code: 201 884-5485

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, par value $0.001 per share	SCYX	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 10, 2024, SCYNEXIS, Inc. (the "Company") updated its investor slide presentation ("Corporate Presentation"). The Corporate Presentation is available on the Company's website and is furnished as Exhibit 99.1 hereto.

The information in this Item 7.01 and Exhibit 99.1 hereto are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Corporate Presentation
100	Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SCYNEXIS, Inc.

Date: September 9, 2024

By: /s/ David Angulo, M.D.
Name: David Angulo, M.D.
Its: Chief Executive Officer

A dynamic force in the fight against infectious disease

September 2024

Forward-Looking Statement

Certain statements regarding SCYNEXIS, Inc. (the "Company") made in this presentation constitute forward-looking statements, including, but not limited to, statements regarding our business strategies and goals, plans and prospects, market size, adoption rate, potential revenue, clinical validity and utility, growth opportunities, future products and product pipeline. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited, to: BREXAFEMME may not be accepted by physicians and patients at the rate SCYNEXIS expects; risks inherent in SCYNEXIS' ability to successfully develop and obtain FDA approval for ibrexafungerp for additional indications; unexpected delays may occur in the timing of acceptance by the FDA of an NDA submission; the anticipated filing of the Company's request to the FDA to lift the clinical hold on the MARIO study and its filing timing; the expected costs of commercializing BREXAFEMME or of clinical studies and when they might begin or be concluded; the commercial opportunity and timing of clinical development for SCY-247; SCYNEXIS' need for additional capital resources; and SCYNEXIS' reliance on third parties to conduct SCYNEXIS' clinical studies and commercialize its products. The use of words such as "anticipates," "expects," "intends," "plans," "could," "should," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions are intended to identify forward-looking statements, but not all forward-looking statements may be so identified. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent reports filed with the Securities and Exchange Commission ("SEC"), including under the caption "Risk Factors" in the Company's annual report on Form 10-K for the year ended December 31, 2023, and in the Company's subsequent quarterly reports on Form 10-Q, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation, or to reflect actual outcomes.

Scynexis Corporate Update – September 2024

GSK Amended Agreement Including Path Forward for Restart of the MARIO Study

Total potential deal value of up to $448 million plus royalties. $115 million already received.

SCY-247 Update

New promising pre-clinical data presented at Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in April 2024

Phase 1 study initiation planned for Q4 2024

FURI / CARES / NATURE/ SCYNERGIA / VANQUISH Studies Update

Studies completed. Clinical Study Reports for FURI, CARES and NATURE delivered to GSK, triggering a $10 million development milestone to Scynexis.

MARIO Study

We anticipate filing our request with the FDA in Q4 of 2024 to lift the MARIO study clinical hold.

Strong Balance Sheet

Cash runway > 2 years ($83.7 million in cash, cash equivalents and investments as of 6/30/2024 not including the recently achieved $10 million development milestone to be paid to us in Q3 of 2024)

Limited Antifungal Development Coupled With Escalating Resistance Has Resulted in Substantial Public Health Burden

SCYNEXIS aims to address antimicrobial resistance (AMR) by bringing a ground-breaking class of drugs with the strength, safety and versatility to defeat even the most insidious fungal diseases



Fungal Resistance a Growing, Global, Public Health Threat

Antifungal development is a well-recognized priority

WHO Releases First-Ever List of Priority Deadly Fungal Pathogens

Fungal Outbreaks Increasing



CDC Identifies Drug Resistant *Candida* spp. and *C. auris* as Serious and Urgent Threats

BARDA New Priority: Antifungals



PASTEUR Act renews focus on antimicrobial resistance

SCYNEXIS

Fungerps are Well-Suited to Address High Priority Fungal Pathogens

Demonstrated activity vs. fungi in both critical and high priority WHO Fungal Priority Pathogens list[1]

SCY-247 (IV and oral):
Significant opportunity based on broad spectrum activity and fungerp-like tolerability

Ibrexafungerp:
GSK estimated opportunity as >$500M based on broad coverage of key pathogens[2]

	Fungerps	Echinocandin	Azole	Polyene
Companies	SCYNEXIS (SCY-247) GSK (Ibrexafungerp)	Pfizer astellas MERCK	Pfizer astellas MERCK	GILEAD astellas Leadiant Biosciences
Peak Sales per Product	> $500M (potential)[2]	~$370M to $680M[3]	~$720M to >$1B[3]	~$500M[3]

SCYNEXIS

1. www.who.int/news/item/25-10-2022-who-releases-first-ever-list-of-health-threatening-fungi
2. GSK press briefing on SCYNEXIS/BREXAFEMME March 30, 2023
3. Based on company filings and Symphony data (US)

Opportunities to Grow Shareholder Value

Advancing proprietary platform of triterpenoid fungerps while evaluating next generation innovations



Maximize Ibrexafungerp opportunity

Partnership with GSK optimizes BREXAFEMME commercial potential in VVC and RVVC

SCYX continued execution of development activities to ensure full value potential is realized



Advance next generation fungerp

SCY-247 in invasive fungal infections with critical needs

- Leverages core internal expertise
- Addresses recognized unmet needs with significant market potential

Strengthened balance sheet enhances the opportunity to deliver **additional innovative therapies** to patients with significant unmet need

Ibrexafungerp GSK Licensing Agreement, As Amended December 2023

Total deal value of up to $448 million plus royalties



SCYNEXIS

Fungerp Pipeline

A New Class of Antifungals – Powerful - Different



SCYNEXIS *Partially Supported by NIH

SCY-247:
Next Generation Fungerp

SCYNEXIS

SCY-247 – Our Next Generation Fungerp



BROAD SPECTRUM OF ACTIVITY

Fungicidal against *Candida* spp.

Including *Candida auris* and other echinocandin-resistant *Candida* spp.

Active against MDR pathogens

Including azole-resistant *Aspergillus* spp.

Other fungal pathogens

Yeasts, molds, *Pneumocystis* and dimorphic fungi

VALIDATED MOA

Glucan synthase inhibitor

Glucan synthase not found in human cells

Echinocandin MOA

Same MOA as echinocandins, with differentiated binding

Active against most echinocandin-resistant *Candida* strains

FAVORABLE PK PROFILE

Suitable for IV and oral formulations

Low propensity for DDIs

Tissue penetration

Distributes into tissues often affected by fungal infections

SCY-247 – In Development Against Resistant Fungal Infections

Anticipated Qualified Infectious Disease Product (QIDP) designation, Orphan Drug Designation and Fast Track (regulatory exclusivity of at least 10 years)

IP wholly owned by SCYNEXIS

Development backed by NIH

NIH provided ~$3M funding to Case Western University for development of SCY-247 against *C. auris*

IND-enabling studies in progress

Phase 1 study initiation anticipated in Q4 2024

SCY-247 – Our Next Generation Fungerp

Scientific Meeting Data

11th Congress on Trends in Medical Mycology (TIMM) – October 2023

- Potent and broad-spectrum *in vitro* activity, including against a large array of yeasts, molds and dimorphic fungi
- Extensive tissue distribution in animal models
- Fungicidal activity against multi-drug resistant strains, including *Candida albicans* and *Candida auris*
- *In vivo* efficacy in a mouse model of invasive candidiasis

11th Advances Against Aspergillosis and Mucormycosis (AAAM) Conference – January 2024

- *In vivo* efficacy in treating a Mucorales pulmonary infection in immunosuppressed mice
  - Efficacy of SCY-247 was equivalent to antifungals currently used to treat mucormycosis
  - The combination of SCY-247 with liposomal amphotericin B resulted in a statistically significant survival improvement when compared to either monotherapy

SCY-247 – Our Next Generation Fungerp

Scientific Meeting Data

Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID) – April 2024

- *SCY-247* demonstrated *in vitro* activity against a broad range of pathogenic fungi, including azole-resistant strains of *Candida* and *Aspergillus* species
  - The most potent activity was observed against *Candida* and *Aspergillus* species and the dimorphic fungi *B. dermatitidis*, *H. capsulatum*, and *Coccidioides* species
- SCY-247 treatment significantly inhibits the growth of both susceptible and multi-drug resistant *C. auris* strains
- SCY-247 had a prominent effect on the fungal cell morphology

SCY-247 – Our Next Generation Fungerp

Scientific Meeting Data

Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID) – April 2024

- SCY-247 significantly reduced fungal burden in kidneys and lungs of *in vivo* model of invasive candidiasis caused by *Candida glabrata,* the 2nd most common *Candida* species found in patients with invasive disease at many institutions
- In contrast, caspofungin significantly lowered fungal burden within the kidneys but not the lungs, while fungal burden in mice treated with fluconazole was similar to controls in both organs

Significant, dose-dependent reductions in kidney and lung fungal burden in SCY-247-treated mice



SCYNEXIS Strongly Positioned for Value Creation

- Category leader in the fight against deadly fungal pathogens with new antifungal (SCY-247) in development
- Global urgency to rapidly develop potent antifungals to treat emerging infectious threats
- Demonstrated internal expertise, solid supply chain and long IP protection, and potential for next generation products and partnerships
- Strong Balance Sheet with cash runway of more than 2 years